Blue Earth launches phase III trial for PET agent

By staff writers

March 17, 2020 -- Bracco molecular imaging subsidiary Blue Earth Diagnostics said that a phase III clinical trial of its investigational radiohybrid PET imaging agent for prostate cancer is now underway.

The Lighthouse clinical trial is a multicenter, single-arm study in the U.S. and Europe that will evaluate the safety and diagnostic performance of the company's investigational prostate-specific membrane antigen-targeted radiohybrid PET imaging agent -- rhPSMA-7.3 (18F) -- in men with newly diagnosed prostate cancer. The trial will determine the sensitivity and specificity of the agent for detecting pelvic lymph node metastases in comparison with surgical pathology, according to the company.

The initial patient in the study was dosed at RadNet's Liberty Pacific Advanced Imaging Center in Los Angeles, Blue Earth said.

Copyright © 2020

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking